Hypermarcas (OTCMKTS:HYPMY) Issues Earnings Results

Hypermarcas (OTCMKTS:HYPMY) announced its earnings results on Wednesday. The company reported $0.13 earnings per share (EPS) for the quarter, Zacks reports. The business had revenue of $408.83 million for the quarter. Hypermarcas had a return on equity of 6.19% and a net margin of 11.28%.

Hypermarcas Stock Performance

Shares of Hypermarcas stock traded up $0.06 during trading on Thursday, hitting $4.99. 94,981 shares of the stock were exchanged, compared to its average volume of 8,645. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.80 and a current ratio of 1.26. Hypermarcas has a 12 month low of $2.64 and a 12 month high of $5.12. The stock’s fifty day moving average is $4.30 and its 200 day moving average is $4.42. The stock has a market cap of $3.16 billion, a PE ratio of 23.76 and a beta of 0.82.

Wall Street Analysts Forecast Growth

Separately, Scotiabank upgraded Hypermarcas to a “strong-buy” rating in a research note on Thursday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat.com, Hypermarcas currently has a consensus rating of “Strong Buy”.

About Hypermarcas

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.